Join FDLI for our upcoming program—Pharmacy Compounding: An FDLI Dialogue—on February 12 in Washington, DC. In an open, balanced format, experts will discuss and debate the regulation of pharmacy compounding, providing a historical framework and exploring recent developments. Participants will delve into key questions about policy, surveillance and enforcement, legislative and oversight issues. Discussion will address unresolved questions related to defining "compounding" and "manufacturing", as well as how the courts and Congress have interpreted FDA’s authority and role in regulating pharmacy compounding. With newly proposed legislation, the courts split, and statutory authority at issue, this is the ideal time for stakeholders to convene, communicate, and look ahead to what is next.
More About FDLI Dialogues
FDLI Dialogues are convened for stakeholders to discuss evolving policy in emerging areas of food and drug law. With the focus on audience participation and discussion, these are not typical panel- and speaker-focused educational programs. Dialogues are typically half-day programs, often offered with the option to participate in-person or by teleconference.
Who Should Attend
- Attorneys, regulatory staff and compliance personnel who work in the pharmaceutical industry for corporations and manufacturers of drugs
- Regulatory affairs professionals and scientists who work in the area of compounding
- Pharmacists, medical professionals, public health and consumer advocates, and other individuals working on pharmacy law, policy, and legislation
- Academics and other research organizations and members of the press who study and report on issues related to drug safety and law